Ocera Starts Second Part of Trial of OCR-002 for Liver Disease That Impacts Mental Functioning
News
Ocera Therapeutics has started the second part of a Phase 1/2a clinical trial of OCR-002 (ornithine phenylacetate) tablets as a treatment for a liver disease known as hepatic encephalopathy (HE). The ... Read more